梅州打胎得需要多少钱梅州20周流产的费用,梅州超导人流费用,梅州假体隆鼻一般费用,梅州白带异常的治疗去哪家医院蕞好,梅州好妇科病医院,梅州月经长期走什么原因,梅州3个月人流所需费用

SAN FRANCISCO, Nov. 3 (Xinhua) -- Hewlett-Packard Co. (HP) on Thursday introduced its Slate 2 Tablet PC, a business-targeted tablet computer running Windows operating system.Looking like the previous version, Slate 2, featuring an 8.9- inch screen, is upgraded with Intel Atom Z670 processor to deliver faster boot times and improved battery life up to six hours, said HP.It also has a Bluetooth keyboard dock and Swype keyboard which allows users to enter words by sliding a finger or stylus from letter to letter, lifting only between words.The device will be available to customers worldwide for 699 U.S. dollars later this month, according to HP.Slate 500, Slate 2's previous generation running Windows, was introduced last October and sold exclusively to businesses for 800 dollars upon launch.HP said in a statement that the Slate 2 tablet provides instant deployment for business and vertical markets such as education, healthcare, government and retail, where jobs frequently take users away from a traditional desk.The company on Thursday also announced HP 3115m, a new notebook PC targeting business, education and government customers. The notebook will be available in the Americas only next Friday with prices staring at 429 dollars.HP's consumer-oriented tablet TouchPad was killed off in August before former chief executive officer Leo Apotheker resigned. A dropped price from 499 to 99.99 dollars has made the unpopular device sold out in stores across the U.S. and Canada in days.Last Thursday, HP announced it will keep its PC business, saying it will build tablets running Microsoft's upcoming Windows 8 system in 2012.

WASHINGTON, Nov. 25 (Xinhua) -- In the United States, the AIDS epidemic has plateaued, but it is still at "unacceptable high" level, a U.S. expert said ahead of the World AIDS Day."The situation is stable in the United States, stable in an unacceptable high level for at least 10 years and has not gone down. It's still a serious problem," Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), told Xinhua in an exclusive interview.According to Fauci, there are about 1.1 million people infected with HIV in the U.S., of which about 20 percent do not know they are infected. Those are the ones that more likely will infect other people. Since the world's first AIDS case was reported 30 years ago, the U.S. has seen close to 600,000 AIDS-related death. And among the 65,000 new infections each year in the U.S, about 50 percent are African Americans. In the United States, about 12 percent of the population is African American."Our new approach to prevention is to try and get access at community level, to people at most risk, to seek out to voluntarily test, to link them to care, and to automatically get them treatment," said Fauci. "When you get someone on treatment, it is extremely unlikely that they will infect their sexual partner."Fauci thought the international community's battle against the HIV/AIDS has gotten better over the last 30 years.Early on, when the disease was inaccurately thought to be a disease of developed world. There was a denial in many countries in Asia, in Southern Africa, South America and Caribbean, that this will turn out to be an extraordinary problem in those countries. As the years went by, it was clear that it was not a disease of gay men in the United States and the developed world. It was a disease mostly in the developing world when 90 percent of new infections occur in low- and middle-income countries and 67 percent of the cases are in Southern Africa."The response of the global community first was denial and not full appreciation of the potential impact of the pandemic. As the years have gone by, the response has been better and better," said Fauci, an immunologist that has made substantial contributions to research in the areas of AIDS and other immunodeficiencies, both as a scientist and as the head of NIAID.The advance in the arena of therapy with drugs has been " spectacular" and "very impressive", he said.In the early 1980 before there were any drugs, the median survival period of people in the United States who was infected with HIV, was about six to eight months. "Today in 2010, if someone was newly infected with HIV and he's 20-25 years old, and you put them on therapy, you can predict mathematically that they will live additional 50 years," said Fauci.Over the last couple of years, there has been "significant but slow" advances with vaccines against HIV. For example, there was a trial that was conducted in Thailand in which there was a modest degree of efficacy, about 31 percent of protection."That's not enough to have a vaccine available for widespread use but give us some important clues into what next generation of vaccines would be," said Fauci.As to the "three zeros" target adopted by the United Nations this year, Fauci said that it's "aspirational but not gonna be easy.""It is good to set very high goals for the future. I don't think that we realistically are gonna get to zero new infections, zero new discrimination, zero (AIDS-related) death in the next few years," said Fauci. "I think it will take several years to get there. I believe that if more countries and the international community are engaged to play a role in trying to stop HIV, to prevent and treat and care for HIV-infected individuals, that we will automatically achieve that objective."

BEIJING, Jan. 10 (Xinhua) -- China's energy chief said here Tuesday that the country is under greater pressure to ensure energy supply this year as both demand and international competition for resources grows.Liu Tienan, head of the National Energy Administration (NEA), made the remarks when speaking at a national energy work conference."It is always worrisome to have to sustain supply of energy and resources for a country with 1.3 billion people," Liu said.As China is facing a "grim situation" in energy saving and emission reduction, Liu noted, it is urgent to restructure the country's energy use and control the gross consumption volume this year.To ensure a stable energy supply, China will optimize the layout of energy exploration, start construction of energy-transmission projects and other major energy programs while boosting reserves of oil, natural gas and coal in 2012, Liu said.The NEA plans to add another 200 metric tons to the country's coal-producing capacity this year plus 70 million kw of new installed power-generating capacity.If the ecology is protected and people are relocated, China will start construction of hydropower projects of 20 million kw in 2012, according to the NEA.Once safety is ensured, nuclear power will be developed after the country's new safety plan is approved.As for renewable energy development, the NEA plans to launch wind power projects with a total capacity between 15 million kw and 18 million kw, while developing 3 million kw of solar power over the new five-year period ending 2015.Liu said, in 2012, the country aims to provide electricity to another 600,000 people who currently have no access to it and expand electricity access to 5 million people by 2015.The NEA has budgeted 65 billion yuan (10.3 billion U.S. dollars) for upgrading the grids in rural areas.Over the next four years, China will facilitate the development of non-conventional natural gas, such as shale gas and coalbed methane by increasing the number of natural gas users by 100 million to 250 million.A key indicator measuring the economic vitality, power consumption rose 11.7 percent year-on-year to 4.7 trillion kWh in China in 2011. The growth in 2012 is expected to slow to 8.5 percent amid the country's economic slowdown.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.